SCHEMBL3001111

SCHEMBL3001111

Cc1cccc(C)c1-c1csc(N2CCN(S(=O)(=O)c3ccc(Br)cc3Cl)CC2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPT P10636 3/20 0.46
LMNA P02545 2/20 0.46
ALDH1A1 P00352 2/20 0.46
MAPK1 P28482 2/20 0.44
USP2 O75604 1/20 0.43
RECQL P46063 1/20 0.43
HSD17B10 Q99714 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
TP53 P04637 2/20 0.41
PTPN1 P18031 1/20 0.40
PTPN6 P29350 1/20 0.40
CDC25A P30304 1/20 0.40
PKM P14618 1/20 0.39
RAB9A P51151 1/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
ABL1 P00519 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3652517 0.94 MAPT (0.41) SMN1; SMN2MEN1KMT2AMAPTLMNA
SCHEMBL3011127 0.92 SMN1; SMN2 (0.42) SMN1; SMN2MEN1KMT2AMAPTLMNA
SCHEMBL3015903 0.90 MAPT (0.47) SMN1; SMN2MEN1KMT2AMAPTLMNA
SCHEMBL3014561 0.90 MEN1 (0.44) SMN1; SMN2MEN1KMT2AMAPTLMNA
SCHEMBL3018270 0.89 MEN1 (0.46) SMN1; SMN2MEN1KMT2AMAPTLMNA
SCHEMBL3015046 0.88 SMN1; SMN2 (0.55) SMN1; SMN2MEN1KMT2AMAPTLMNA
SCHEMBL3001220 0.87 SMN1; SMN2 (0.48) SMN1; SMN2MEN1KMT2AMAPTLMNA
SCHEMBL3011983 0.87 KMT2A (0.54) SMN1; SMN2MEN1KMT2AMAPTLMNA
SCHEMBL3016064 0.87 MAPT (0.50) SMN1; SMN2MEN1KMT2AMAPTLMNA
SCHEMBL15671704 0.86 SMN1; SMN2 (0.52) SMN1; SMN2MEN1KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885MEN1 454/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.